The earnings call highlighted strong growth in key products and successful new product launches, particularly in the HIV prevention and oncology segments. However, there were declines in Veklury and cell therapy sales, which were offset by the overall robust performance of the base business.

Company Guidance -

Q3 2025

During Gilead's Second Quarter 2025 Earnings Conference Call, the company shared robust financial and clinical advancements, highlighted by the FDA approval of lenacapavir, branded as Yeztugo, for twice-yearly HIV prevention. Excluding Veklury, base business sales reached $6.9 billion, reflecting a 4% year-over-year growth, with HIV sales alone contributing $5.1 billion, marking a 7% increase driven by Biktarvy's 9% growth to $3.5 billion and Descovy's 35% rise to $653 million. Product sales totaled $7.1 billion, up 2% year-over-year, although partially offset by reduced Veklury sales due to declining COVID-19 hospitalizations. The company raised its full-year revenue and EPS guidance, forecasting HIV sales growth of approximately 3% for 2025. Additionally, Gilead emphasized strong commercial execution and strategic pipeline developments in oncology and cell therapy, with advancements in Trodelvy for breast cancer and promising data from the iMMagine-1 trial for anito-cel in multiple myeloma.

Strong Base Business Performance

Base business sales of $6.9 billion grew 4% year-over-year, driven by strong growth in Biktarvy, Descovy, Livdelzi, and Trodelvy. Total product sales grew 2% year-over-year to $7.1 billion.

Successful Launch of Yeztugo

FDA approval of lenacapavir (Yeztugo) as the first twice yearly injection for HIV prevention. Yeztugo's launch has been described as one of the best-planned commercial launches with significant early awareness and access gains.

Trodelvy Positive Phase III Results

Trodelvy demonstrated highly statistically significant and clinically meaningful efficacy in the first-line setting for metastatic triple-negative breast cancer.

Increased Full-Year Guidance

Full-year revenue and EPS guidance have been increased due to strong commercial execution and operational discipline.

Positive Momentum in HIV Market

HIV sales grew 7% year-over-year. Biktarvy sales grew 9% to $3.5 billion, and Descovy sales surged 35% to $653 million.

Positive CHMP Opinion for Yeztugo

The European Medicines Agency's CHMP issued a positive opinion for lenacapavir, indicating strong international growth potential.

Gilead Sciences (GILD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GILD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	2.16 / -	2.02	―	―	―
Aug 07, 2025	2025 (Q2)	1.96 / 2.01	2.01	0.00% (0.00)
Apr 24, 2025	2025 (Q1)	1.78 / 1.81	-1.32	237.12% (+3.13)
Feb 11, 2025	2024 (Q4)	1.74 / 1.90	1.72	10.47% (+0.18)
Nov 06, 2024	2024 (Q3)	1.53 / 2.02	2.29	-11.79% (-0.27)
Aug 08, 2024	2024 (Q2)	1.61 / 2.01	1.34	50.00% (+0.67)
Apr 25, 2024	2024 (Q1)	-1.49 / -1.32	1.37	-196.35% (-2.69)
Feb 06, 2024	2023 (Q4)	1.76 / 1.72	1.67	2.99% (+0.05)
Nov 07, 2023	2023 (Q3)	1.92 / 2.29	1.9	20.53% (+0.39)
Aug 03, 2023	2023 (Q2)	1.64 / 1.34	1.58	-15.19% (-0.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GILD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$110.28	$119.41	+8.28%
Apr 24, 2025	$105.40	$102.44	-2.81%
Feb 11, 2025	$94.80	$101.87	+7.46%
Nov 06, 2024	$89.66	$95.73	+6.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Gilead Sciences (GILD) report earnings?

Gilead Sciences (GILD) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is Gilead Sciences (GILD) earnings time?

Gilead Sciences (GILD) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GILD EPS forecast?

GILD EPS forecast for the fiscal quarter 2025 (Q3) is 2.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing